Gut microbiota have a role in MS pathogenesis and may also influence MRI findings. Dr Federico Montini (Brigham and Women's Hospital, Boston, MA, USA) and his group set out to investigate if gut microbiota are associated with 7T MRI metrics (notably cerebral LME and cortical lesions [CL]) in MS. Dr Montini explained that they included 28 patients with MS with a median age of 53 years. Participants underwent 7T MRI scans and their stools were collected within 6 months after the scan.
The results showed that gut microbiota were associated with LME foci count, CL count and volume, and T2-lesion volume. “It was very interesting to see that several butyrate-producing bacteria, such as Roseburia, Agathobacter, and Blautia, had a beneficial effect on LME (i.e. less LME foci), whereas Alistipes onderdonkii and Ruminococcus had a detrimental effect.” The volumetric data analysis revealed that gut microbiota are associated with volumes of the thalamus, caudate, globus pallidus, putamen, and deep grey matter; Butyrococcus and Prevotella had a beneficial effect (i.e. less atrophy), while for example Collinsella intestinales had a detrimental effect.
Stool MUC2 levels were reduced in MS. MUC2 is a major structural component of the protective mucus layer in the colon and small intestine. Stool MUC2 levels were negatively associated with LME foci count and negatively associated with mucus-degrading bacteria abundance.
Dr Montini concluded that these findings may indicate that disruption of the mucus layer facilitates a (too) narrow bacterial-immune system interaction, favouring LME development.
- Montini F, et al. Gut microbiota are associated with cortical lesions and leptomeningeal enhancement on 7T MRI. Abstract O008, ECTRIMS 2024, 17–20 October 2024, Copenhagen, Denmark.
Medical writing support was provided by Michiel Tent
Copyright ©2024 Medicom Medical Publishers
Posted on
Previous Article
« ESMO 2024 Focus on GU Oncology Podcast Next Article
High-dose simvastatin does not slow disability progression in SPMS »
« ESMO 2024 Focus on GU Oncology Podcast Next Article
High-dose simvastatin does not slow disability progression in SPMS »
Related Articles
August 18, 2021
Alemtuzumab in treatment-naïve patients with aggressive MS
November 8, 2019
Risk of hypogammaglobulinemia and rituximab
September 10, 2020
Serum NfL predicts long-term clinical outcomes in MS
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com